Anthropic has continued its push into the healthcare sector by acquiring New York startup Coefficient Bio, a specialist in applying AI to drug discovery that was set up last year but until now has ...

Lunsekimig is one of a trio of clinical candidates that Sanofi is developing as successors to its big-selling IL-3 and IL-13 ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation.

Neurocrine Biosciences has agreed a $2.9 billion deal to buy Soleno Therapeutics and its treatment for a rare, genetic form ...

By utilising augmented intelligence early, small and mid-sized companies can maximise their innovation potential, minimise ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

His teams are trained to read where it will be three passes from now. In Formula 1, race strategy is no longer a gut call at ...

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a ...

AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

Large-scale flow cytometry delivers critical biological insight by enabling multidimensional analysis of individual cells, ...

Trump started the Section 232 probe into pharma in the spring of 2025, using it as a lever for trade negotiations and MFN ...

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...